Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance
NCT07132567
·
clinicaltrials.gov ↗
RECRUITING
Status
15
Enrollment
INDUSTRY
Sponsor class
Conditions
Mycosis Fungoides
Sezary Syndrome
Interventions
DRUG:
Poteligeo 20mg
Sponsor
Kyowa Kirin Co., Ltd.